Elekta

56,80 SEK

+1,70 %

Mindre end 1K følgere

EKTA B

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+1,70 %

+22,10 %

+28,22 %

+13,69 %

-7,11 %

-8,90 %

-8,21 %

-48,18 %

+551,12 %

Elekta operates in the medical technology industry and focuses on the development, manufacture and distribution of medical equipment for cancer treatment and neurosurgery. The company's products include radiotherapy machines and diagnostic imaging systems. The business has a global market position. Elekta was founded in 1972 and is headquartered in Stockholm.

Markedsværdi

21,79 mia. SEK

Aktieomsætning

58,28 mio. SEK

Omsætning

18,02 mia.

EBIT %

4,94 %

P/E

91,61

Udbytteafkast, %

4,23 %

Omsætning og EBIT-margin

Omsætning mia.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

5.3

2026

Delårsrapport Q3'26

5.3

2026

Halvårligt udbytte

28.5

2026

Årsrapport '26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse26.11.2025, 06.30

Second quarter, August–October 2025/26

Pressemeddelelse12.11.2025, 06.30

Invitation to the presentation of Elekta’s second quarter 2025/26

Selskabsmeddelelse31.10.2025, 06.30

Elekta’s Nomination Committee for the Annual General Meeting 2026

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse9.10.2025, 05.30

New impact report reveals radiotherapy’s role in cancer care

Pressemeddelelse29.9.2025, 18.10

Study shows MRI-guided adaptive radiotherapy with Elekta Unity improves patient-reported urinary symptoms in men with prostate cancer

Pressemeddelelse25.9.2025, 05.30

Elekta marks two millionth patient treated with Leksell Gamma Knife radiosurgery

Selskabsmeddelelse8.9.2025, 05.30

Elekta announces changes in Executive Management

Selskabsmeddelelse4.9.2025, 14.56

Report from the Annual General Meeting 2025 of Elekta

Selskabsmeddelelse28.8.2025, 05.30

Interim report, First quarter May–July 2025/26

Pressemeddelelse7.8.2025, 05.30

Invitation to the presentation of Elekta’s first quarter 2025/26

Selskabsmeddelelse1.8.2025, 05.30

Notice to the Annual General Meeting of Elekta AB (Publ)

Pressemeddelelse23.7.2025, 13.00

Elekta receives U.S. FDA 510(k) clearance for its Gamma Knife radiosurgery system to treat patients with refractory, drug-resistant mesial temporal lobe epilepsy

Selskabsmeddelelse4.7.2025, 11.30

Elekta's Annual Report for 2024/25 available

Pressemeddelelse12.6.2025, 05.30

Nomination Committee’s proposal for the Board of Directors prior to Elekta’s Annual General Meeting 2025

Pressemeddelelse10.6.2025, 09.00

Elekta leaders present retrospective and future developments to investor community

Selskabsmeddelelse9.6.2025, 17.00

Elekta appoints Jakob Just-Bomholt as new President and CEO

Pressemeddelelse5.6.2025, 05.30

Elekta to enhance cancer treatment in Croatia through strategic acquisition

Selskabsmeddelelse28.5.2025, 05.30

Year-end report May–April 2024/25

Pressemeddelelse13.5.2025, 05.30

Invitation to the presentation of Elekta’s fiscal year 2024/25

Pressemeddelelse3.5.2025, 13.45

Clinical trial shows more precise radiotherapy using Elekta Unity MR-Linac preserves sexual function in men with prostate cancer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.